文献速递免疫规划

乌干达9-23月龄儿童接种五分之一剂与二分之一剂黄热病疫苗后不良事件比较:2019-2020年初步报告

Adverse events following immunization (AEFI) with fractional one-fifth and one-half doses of yellow fever vaccine compared to full dose in children 9-23 months old in Uganda, 2019-2020 - Preliminary report.
PubMed 文献 · Vaccine · 2024-08-15

在乌干达三个研究点招募9-23月龄儿童,开展单盲随机对照试验,比较Bio-Manguinhos 17DD黄热病疫苗五分之一剂、二分之一剂与全剂量接种后28天主动监测的不良事件。共纳入1053名儿童,672名(64%)报告非严重不良事件,17名(2%)报告严重不良事件,各研究组间不良事件频率或严重程度无显著差异;未发现疫苗相关严重不良事件。

要点

  • 9-23月龄儿童接种黄热病疫苗后最常见不良事件为腹泻355名(34%)、发热338名(33%)、皮疹188名(18%)。
  • 17名(2%)报告严重不良事件,其中8名报告惊厥,5名因惊厥或其他原因住院,4例死亡发生在接种28天后。
  • 各研究组间不良事件频率或严重程度无显著差异,未发现疫苗相关严重不良事件。

核心结论

  • 通过全面主动监测,未在9-23月龄接种黄热病疫苗(包括分剂量)的儿童中发现非预期安全性问题。
  • 虽然严重和非严重不良事件报告数较高,但均判定与黄热病疫苗接种无因果关系。
  • 结果为9-23月龄儿童分剂量黄热病疫苗接种的安全性提供了证据。

研究设计与样本

  • 单盲随机对照试验,在乌干达三个研究点招募9-23月龄接受常规儿童保健服务的儿童。
  • 比较Bio-Manguinhos 17DD黄热病疫苗五分之一剂、二分之一剂与全剂量的免疫原性和安全性,本文报告安全性中期分析。
  • 数据收集时间为2019年3月26日至2020年8月31日,接种后28天主动监测所有免疫接种后不良事件(AEFI),使用包括日记卡和客观发热测量在内的多种收集工具。
  • 由乌干达国家AEFI委员会独立团队根据布莱顿协作标准(Brighton Collaboration Criteria)调查和分类严重AEFI(SAE)。

主要发现

  • 共纳入1053名儿童,672名(64%)报告非严重AEFI(NSAE),17名(2%)报告SAE。
  • 最常见AEFI为腹泻355名(34%)、发热338名(33%)、皮疹188名(18%)。
  • 17名SAE中,8名报告惊厥,5名因惊厥或其他原因(呼吸道症状、胃肠道疾病、疟疾)住院,4例死亡发生在接种后超过28天。
  • 未报告预设或疫苗相关SAE,各研究组间不良事件频率或严重程度无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本文为中期分析,标题标注为初步报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2016, the World Health Organization recommended that a fractional dose of yellow fever (YF) vaccine could be used in persons 2 years of age or older in response to an emergency that resulted in a global shortage of available YF vaccine. However, this recommendation did not extend to the youngest age group licensed for YF vaccine because there were no published data on the use or safety of fractional dose YF vaccination in children aged 9-23 months. We conducted a single-blind randomized controlled trial, comparing the immunogenicity and safety of fractional one-fifth and one-half doses of Bio-Manguinhos 17DD YF vaccine with full dose in children aged 9-23 months old in Uganda. In this paper, we present the interim analysis on safety. METHODS: Children aged 9-23 months presenting for routine well-child services were recruited for inclusion at one of three study sites. We collected data during March 26, 2019-August 31, 2020, on all adverse events following immunization (AEFI) during active surveillance for 28 days post-vaccination using multiple collection tools including a diary card with an objective measurement of fever. An independent team from the Uganda national AEFI Committee investigated and classified serious AEFI (SAE) according to Brighton Collaboration Criteria. RESULTS: Among 1053 enrolled children, 672 (64%) were reported to have a non-serious AEFI (NSAE) and 17 (2%) were reported to have a SAE. The most common AEFI were diarrhoea, fever, and rash, each reported by 355 (34%), 338 (33%), and 188 (18%) participants, respectively. Among 17 participants with SAE, eight were reported to have had seizures and five were hospitalised for seizures or other causes (respiratory symptoms, gastrointestinal illness, malaria). Four SAEs (deaths) occurred >28 days after vaccination. There were no reported cases of pre-specified or vaccine-related SAEs. We observed no significant difference in frequency or severity of adverse events among the study groups. CONCLUSIONS: Using comprehensive active surveillance monitoring, we did not identify any unexpected safety concerns among children aged <2 years receiving YF vaccination, including with the fractional doses. Although we identified a high number of both serious and non-serious AEFI, none were determined to be causally related to YF vaccination. These results provide evidence for the safety of fractional dose YF vaccination among children aged 9-23 months.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Casey RM, Najjengo MS, Lubega I, et al. Adverse events following immunization (AEFI) with fractional one-fifth and one-half doses of yellow fever vaccine compared to full dose in children 9-23 months old in Uganda, 2019-2020 - Preliminary report. Vaccine. 2024. PMID: 39153293. doi:10.1016/j.vaccine.2024.126197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。